株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

B型肝炎:世界の治験レビュー

Hepatitis B Global Clinical Trials Review, H2, 2016

発行 GlobalData 商品コード 217846
出版日 ページ情報 英文 785 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GlobalData社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
B型肝炎:世界の治験レビュー Hepatitis B Global Clinical Trials Review, H2, 2016
出版日: 2016年08月24日 ページ情報: 英文 785 Pages
概要

B型肝炎は、B型肝炎ウィルス(HBV)によって感染した肝臓が炎症を起こした疾患です。これは世界でも重大な健康問題の一つであり、ウィルス性肝炎の中でも最も深刻な種類です。子供の方が慢性感染症のリスクが高く、B型肝炎ウイルス(HBV)以外にもアルコールのような毒素によって発生します。また、感染者の血液、精液、膣液、他の体液との接触によっても感染が拡大します。

当レポートでは、B型肝炎に関する臨床研究の最新動向について分析し、疾患・治療法の概要や、G7諸国における治験の状況、地域・フェーズ(相)・段階別の進行状況、有望なスポンサー、各企業・研究機関での研究の進行状況、有望な薬剤の比較といった情報を盛り込んで、お届けします。

イントロダクション

  • B型肝炎
  • 当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • 上位5ヶ国における治験件数; アジア太平洋地域
    • 上位5ヶ国における治験件数; 欧州
    • 主要国における治験件数; 北米
    • 上位5ヶ国における治験件数; 中東/アフリカ地域
    • 上位5ヶ国における治験件数; 中南米

G7諸国における治験件数: B型肝炎治験件数の感染症治験件数に対する比率

フェーズ(相)別治験件数: G7諸国

G7諸国における治験件数:フェーズ(相)別

E7諸国における治験件数: B型肝炎治験件数の感染症治験件数に対する比率

フェーズ(相)別治験件数: E7諸国

E7諸国における治験件数:フェーズ(相)別

フェーズ(相)別治験件数

  • フェーズ(相)別の進行中治験件数

進捗状況別の治験件数

評価項目別の治験件数

未完了の治験 B型肝炎

一定期間に採用された被験者数

スポンサーの種類別の治験件数

有望なスポンサー

治験主要参加企業 - B型肝炎治療薬

有望な薬剤

  • 最新治験ニュース: B型肝炎

治験のプロファイル

  • 代表的な企業の治験の概要
    • GlaxoSmithKline plc
    • Gilead Sciences, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Company
    • Novartis AG
    • Sanofi
    • Bukwang Pharm.Co., Ltd.
    • Dynavax Technologies Corporation
    • LG Life Sciences, Ltd.
  • 代表的な研究機関/病院の治験の概要
    • National Taiwan University Hospital
    • The National Institute of Diabetes and Digestive and Kidney Diseases
    • The National Institute of Allergy and Infectious Diseases
    • Sun Yat-sen University
    • Third Affiliated Hospital of Sun Yat-sen University
    • Yonsei University
    • The Foundation for Liver Research
    • Chinese University of Hong Kong
    • The University of Hong Kong
    • French National Agency for Research on AIDS and Viral Hepatitis

5大治験プロファイル

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC3663CTIDB

GlobalData's clinical trial report, "Hepatitis B Global Clinical Trials Review, H2, 2016" provides an overview of Hepatitis B clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatitis B. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Hepatitis B to Infectious Disease Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Hepatitis B to Infectious Disease Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Hepatitis B Therapeutics Clinical Trials
  • Prominent Drugs
    • Latest Clinical Trials News on Hepatitis B
      • Aug 02, 2016: ContraVir Reports Positive Data from Phase 1b Study of CMX157
      • Jul 21, 2016: Transgene to Continue Phase 1/1b Study with TG1050 in Chronic Hepatitis B Patients on the Recommendation of the Trial's Safety Review Committee
      • Jun 22, 2016: Spring Bank Pharmaceuticals Doses the First Patient in the ACHIEVE Global Phase 2 Program of SB 9200 in Hepatitis B
      • Jun 21, 2016: ContraVir Doses First Patients in Head-to-Head Study of CMX157 vs. Viread for Treating Hepatitis B
      • Jun 07, 2016: Replicor announces publication of its REP 101 study demonstrating the therapeutic effect of NAPs and the achievement of functional control off treatment in human patients with chronic hepatitis B infection
      • Jun 07, 2016: Replicor announces publication of its REP 102 study demonstrating the therapeutic effect of NAPs and the achievement of functional control off treatment in human patients with chronic hepatitis B infection
      • Jun 01, 2016: ContraVir Initiates Head-to-Head Phase 2a Clinical Study of CMX157 vs. Viread for Treating Hepatitis B
      • Jun 01, 2016: Maxwell Biotech Venture Fund's Portfolio Company Hepatera Announces Publication of Myrcludex B Clinical Results in Journal of Hepatology
      • May 25, 2016: Maxwell Biotech Venture Fund's Portfolio Company Hepatera Announces Start Of Second Phase 2 Clinical Trial Of Myrcludex B In Chronic Hepatitis B/D Infection
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Hepatitis B Therapeutics, Global, Clinical Trials by Region, 2016*
  • Hepatitis B Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Hepatitis B Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Hepatitis B Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016*
  • Hepatitis B Therapeutics Clinical Trials, Europe, Top Five Countries, 2016*
  • Hepatitis B Therapeutics Clinical Trials, North America, Top Countries, 2016*
  • Hepatitis B Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016*
  • Hepatitis B Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016*
  • Proportion of Hepatitis B to Infectious Disease Clinical Trials, G7 Countries (%), 2016*
  • Hepatitis B Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Hepatitis B Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Hepatitis B to Infectious Disease Clinical Trials, E7 Countries (%), 2016*
  • Hepatitis B Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Hepatitis B Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Hepatitis B Therapeutics, Global, Clinical Trials by Phase, 2016*
  • Hepatitis B Therapeutics, Global, Clinical Trials In Progress by Phase 2016*
  • Hepatitis B Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Hepatitis B Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Hepatitis B Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Hepatitis B Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016*
  • Hepatitis B Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Hepatitis B Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Hepatitis B Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*

List of Figures

  • Hepatitis B Therapeutics, Global, Clinical Trials by Region (%), 2016*
  • Hepatitis B Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Hepatitis B Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Hepatitis B Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016*
  • Hepatitis B Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016*
  • Hepatitis B Therapeutics Clinical Trials, North America, Top Countries (%), 2016*
  • Hepatitis B Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016*
  • Hepatitis B Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016*
  • Proportion of Hepatitis B to Infectious Disease Clinical Trials, G7 Countries (%), 2016*
  • Hepatitis B Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Hepatitis B Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Hepatitis B to Infectious Disease Clinical Trials, E7 Countries (%), 2016*
  • Hepatitis B Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Hepatitis B Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Hepatitis B Therapeutics, Global, Clinical Trials by Phase (%), 2016*
  • Hepatitis B Therapeutics, Global, Clinical Trials In Progress by Phase, 2016*
  • Hepatitis B Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Hepatitis B Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Hepatitis B Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Hepatitis B Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016*
  • Hepatitis B Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Hepatitis B Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Hepatitis B Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*
  • GlobalData Methodology
Back to Top